{"id":46725,"date":"2026-08-18T14:15:00","date_gmt":"2026-08-18T14:15:00","guid":{"rendered":"http:\/\/www.prnasia.com\/story\/archive\/5028577_AE28577_0"},"modified":"2026-08-18T14:15:00","modified_gmt":"2026-08-18T14:15:00","slug":"genscript-reports-27-3-first-half-2026-revenue-growth-as-ai-drug-discovery-business-doubles","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=46725","title":{"rendered":"GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles"},"content":{"rendered":"\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue<\/i><\/p>\n

PISCATAWAY, N.J.<\/span>, Aug. 18, 2026<\/span> \/PRNewswire\/ — GenScript Biotech Corporation (HKEX: 1548) reported first-half revenue of approximately US$404.2 million on a comparable basis, up 27.3% year over year, while adjusted net profit rose 203.3% to approximately US$62.5 million. The results reflect strong growth across its core businesses, improved operating efficiency, and accelerating demand for AI-enabled drug discovery services.<\/p>\n

\n

\"GenScript<\/a>
GenScript Biotech Corporation reports 27.3% revenue growth in the first half of 2026.<\/span><\/p>\n<\/p><\/div>\n

The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology companies and pharmaceutical innovators. Gene-to-Protein accounted for approximately 66% of GenScript Life Science Group revenue and remained the company’s primary growth engine.<\/p>\n

GenScript’s Gene-to-Protein platform combines scientific expertise, automation, and global manufacturing capacity in an integrated workflow spanning discovery, experimental validation, early development, and production support. As AI increases the scale and complexity of drug discovery, these capabilities help customers validate candidates and advance programs with greater speed and reliability.<\/p>\n

“Our first-half results reflect strong execution across the portfolio, with our core businesses driving both revenue growth and improved profitability,” said Sherry Shao, Rotating CEO of GenScript. “We see significant long-term opportunity as AI reshapes life sciences and increases demand for experimental validation and development services. By expanding our global Gene-to-Protein platform, automation, digital manufacturing, and delivery network, we are strengthening GenScript’s role as a critical infrastructure partner for AI-enabled drug discovery.”<\/p>\n

First-Half 2026 Highlights<\/b><\/p>\n

GenScript Life Science Group<\/b><\/p>\n